Jorge Muñoz, Member of CEFI Board lead the debate on advanced therapies an biological medicinal products.
Sol Ruíz, Jefe de División de Productos Biológicos, Terapias Avanzadas y Biotecnología de la Agencia Española de Medicamentos y Productos Sanitarios and Jordi Faus, Abogado socio de Faus & Moliner Abogados debate about regulation, authorization an development of these products; study of the approved ones; the European Medicine Agency PRIME Scheme that provides early enhanced support to medicines, public financing challenges, no substitution; price differencial between original and biosimilar products; public contracting and their role in hospital enviroment,
Interesting theoretical and practical aspects on dvanced therapies and biological medicinal products.
This post is also available in: Spanish
